Company news
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A (SSE:688505) news
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Aug 13, 2024: Announcement on Interim Profit Distribution Plan 2024
View Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A →
Press releases — page 2
Announcement on Interim Profit Distribution Plan 2024
August 12, 2024
Announcement on Convening Semi-annual Performance Briefing 2024
August 2, 2024
Announcement on Voluntary Disclosure of Completion of the 1st Subject Enrollment in Phase I Clinical Trial of FZ-AD005 Antibody-drug Conjugate for Injection in the Treatment of Advanced Solid Tumors
July 24, 2024
Announcement on Implementation of Dividend Distribution for 2023n
July 5, 2024
Announcement on Cancellation of Partial Special Account for Raised Funds
July 2, 2024
Announcement on Resolutions of 2023 Annual General Meeting
June 27, 2024
Announcement on Progress in Termination of Promotional Service Agreement with Huizheng (Shanghai) Pharmaceuticals Technology Co., Ltd.
June 20, 2024
Announcement on Receiving Government Subsidies
June 17, 2024
Announcement on Using Temporarily Idle Raised Funds for Cash Management
April 29, 2024
Announcement on Attending Pharmaceutical Special Session of 2023 Annual Collective Performance Meeting
April 8, 2024
Announcement on Resolutions of 4th Session of 8th Board of Supervisors
March 28, 2024